trial

The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia

NCTId NCT00495352
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 360 (actual)
Sponsored by Yu-Li Hospital
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
360 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-01
Primary completion
—
Eligibility
ALL · 16 Years · 65 Years

Interventions & indications

Drugs
Hihg-doseNRT, Low-dose NRT, bupropion

Sponsors

Yu-Li HospitalLead Sponsor
National Health Research Institutes, TaiwanCollaborator
Department of Health, Executive Yuan, R.O.C. (Taiwan)Collaborator

Investigators

1
Tsuo-Hung Lan, MD, Ph.DStudy Director

Sites

1 total
Yuli Townhsip, Taiwan

Facts & assertions

3 sourced
Enrollment
360
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Hihg-doseNRT, Low-dose NRT, bupropion
drug
lead_sponsor
Yu-Li Hospital
company
collaborator
National Health Research Institutes, Taiwan
company
Department of Health, Executive Yuan, R.O.C. (Taiwan)
company
indication
Tobacco Use Disorder
indication
Schizophrenia
indication
Tobacco Dependence
indication
investigator
Tsuo-Hung Lan, MD, Ph.D
person